• Product nameAnti-PEX7 antibody
    See all PEX7 primary antibodies
  • Description
    Rabbit polyclonal to PEX7
  • Tested applicationsSuitable for: WB, ELISA, IHC-Pmore details
  • Species reactivity
    Reacts with: Mouse, Human
    Predicted to work with: Rat
  • Immunogen

    Synthetic peptide derived from the internal region of Human PEX7.

  • Positive control
    • Extracts from NIH/3T3 cells. Human breast carcinoma tissue.


  • FormLiquid
  • Storage instructionsShipped at 4°C. Store at -20°C. Stable for 12 months at -20°C.
  • Storage bufferPreservative: 0.02% Sodium Azide
    Constituents: 50% Glycerol, PBS (without Mg2+ and Ca2+), 150mM Sodium chloride, pH 7.4
  • Concentration information loading...
  • PurityImmunogen affinity purified
  • Purification notesab92779 was affinity-purified from rabbit antiserum by affinity-chromatography using an epitope-specific immunogen
  • ClonalityPolyclonal
  • IsotypeIgG
  • Research areas


Our Abpromise guarantee covers the use of ab92779 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
  • Application notesELISA: 1/40000.
    IHC-P: 1/50 - 1/100.
    WB: 1/500 - 1/1000. Predicted molecular weight: 36 kDa.

    Not yet tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • Target

    • FunctionBinds to the N-terminal PTS2-type peroxisomal targeting signal and plays an essential role in peroxisomal protein import.
    • Tissue specificityUbiquitous. Highest expression in pancreas, skeletal muscle and heart.
    • Involvement in diseaseDefects in PEX7 are the cause of peroxisome biogenesis disorder complementation group 11 (PBD-CG11) [MIM:614879]. PBD refers to a group of peroxisomal disorders arising from a failure of protein import into the peroxisomal membrane or matrix. The PBD group is comprised of four disorders: Zellweger syndrome (ZWS), neonatal adrenoleukodystrophy (NALD), infantile Refsum disease (IRD), and classical rhizomelic chondrodysplasia punctata (RCDP). ZWS, NALD and IRD are distinct from RCDP and constitute a clinical continuum of overlapping phenotypes known as the Zellweger spectrum. The PBD group is genetically heterogeneous with at least 13 distinct genetic groups as concluded from complementation studies.
      Defects in PEX7 are the cause of rhizomelic chondrodysplasia punctata type 1 (RCDP1) [MIM:215100]. RCDP1 is characterized by rhizomelic shortening of femur and humerus, vertebral disorders, cataract, cutaneous lesions and severe mental retardation.
      Defects in PEX7 are the cause of peroxisome biogenesis disorder 9B (PBD9B) [MIM:614879]. A peroxisome biogenesis disorder with unusually mild clinical and biochemical manifestations. Affected individuals manifest a variable phenotype similar to, and in some cases indistinguishable from, classic Refsum disease. Variable features include ocular abnormalities, sensorimotor neuropathy, ichthyosis, deafness, chondrodysplasia punctata without rhizomelia or growth failure.
    • Sequence similaritiesBelongs to the WD repeat peroxin-7 family.
      Contains 6 WD repeats.
    • Cellular localizationPeroxisome. Cytoplasm.
    • Information by UniProt
    • Database links
    • Alternative names
      • PBD9B antibody
      • PCDP1 antibody
      • Peroxin 7 antibody
      • Peroxin-7 antibody
      • Peroxisomal PTS2 receptor antibody
      • Peroxisomal targeting signal 2 receptor antibody
      • Peroxisome biogenesis factor 7 antibody
      • Peroxisome targeting signal 2 receptor antibody
      • PEX7 antibody
      • PEX7 protein antibody
      • PEX7_HUMAN antibody
      • PTS2 receptor antibody
      • PTS2R antibody
      • RCDP1 antibody
      • RD antibody
      see all

    Anti-PEX7 antibody images

    • ab92779, at 1/50 dilution, staining PEX7 in paraffin-embedded Human breast carcinoma tissue by Immunohistochemistry in the presence (right panel) or absence (left panel) of immunising peptide.
    • All lanes : Anti-PEX7 antibody (ab92779) at 1/500 dilution

      Lane 1 : Extracts from NIH/3T3 cells
      Lane 2 : Extracts from NIH/3T3 cells with immunising peptide at 10 µg

      Lysates/proteins at 30 µg per lane.

      Predicted band size : 36 kDa

    References for Anti-PEX7 antibody (ab92779)

    ab92779 has not yet been referenced specifically in any publications.

    Product Wall

    There are currently no Abreviews or Questions for ab92779.
    Please use the links above to contact us or submit feedback about this product.